Ftse Mib
35.151,42
0,96%
DAX
18.716,42
-0,12%
S&P 500
5.246,68
0,48%
NASDAQ
16.511,18
0,75%
Bitcoin
61.638,58
0,15%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Virax Biolabs Group Ltd (VRAX) Virax Biolabs Group Ltd (VRAX) Notizie

Virax Biolabs Group Ltd

VRAX
0,755
-0,0383 (-4,83%)
15 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202414:00PRNUSVirax Biolabs Launches Portfolio of Immune Profiling..
16/4/202413:30PRNUSVirax Biolabs to Participate at ESCMID Global 2024
15/3/202421:30PRNUSVirax Biolabs Announces Receipt of NASDAQ Notification..
22/1/202423:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/1/202423:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/1/202413:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202313:34EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202313:30PRNUSVirax Biolabs Forges Strategic Research Collaboration with..
20/12/202322:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
20/12/202322:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202322:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/12/202313:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/12/202313:30PRNUSVirax Biolabs' CEO James Foster Issues Letter to..
18/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
14/12/202313:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202313:30PRNUSVirax Biolabs Group Limited Announces 1-for-10 Share..
08/12/202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/202322:06EDGAR2Form F-3 - Registration statement by foreign private issuers
08/11/202322:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202321:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/10/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202313:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202313:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202313:30PRNUSVirax Biolabs Group Announces Early-Access Program Launch of..
01/9/202313:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/9/202313:30PRNUSVirax Biolabs Group Appoints Dr. Nigel McCracken as Chief..
03/8/202314:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/8/202313:30PRNUSNasdaq Approves 180-Day Extension for Virax Biolabs Group to..
18/7/202313:58EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/7/202313:30PRNUSVirax Biolabs Group Continues Growth and Expansion with the..
14/6/202313:30PRNUSVirax Biolabs' CEO James Foster Issues Letter to..
Apertura: 0,83 Min: 0,7429 Max: 0,83
Chiusura: 0,7933

La tua Cronologia

NASDAQ
VRAX
Virax Biolabs
USOTC
ABQQ
AB (PK)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network